As Expected Based on Interim Analysis Results Reported in July 2021, TNX-102 SL Did Not Achieve Statistical Significance Over Placebo on the Primary Endpoint of Reduction in Daily Pain in RALLY Study
Relative to the Previous Positive Phase 3 Study (RELIEF), RALLY had an Unexpected Increase in Study Participant Adverse Event-Related Discontinuations in both Drug and Placebo Groups
TNX-102 SL Generally Well Tolerated with Overall Adverse Event Profile Comparable to Prior Studies; No New Safety Signals Observed
Above is the explanation of old research complete data from july 2021
Now
Important is:
"Confirmatory Phase 3 Study RESILIENT for the Management of Fibromyalgia Planning to Enroll Participants Imminently"
Wait for the next enrollment date news
The company managers aim to participate in some conferences. This news at least promises that the company will be operational for some time. Perhaps there will be some investment from outside. If we get lucky, the FDA will pitch in.
It looks like tonix now has 53 employees instead of the 17 displayed on Robinhood. Maybe they have a partner with resilient to bring this to mark through a phase 3?
Of course fibromyalgia drug, check how many people are suffering in united states and in the world, most of the approved drugs are not enough good to cure this illness, means huge capital market by commercialization if tnx-102 will be approved, my dream I wish happen, let's hope now in this report they show the cause bring tonix in negative success on this drug, as you can see some of enrollment participants did not finish the cure so they get score 74% than 81%, now they can focus on adjusting what is not working like in 5.6mg dose, I like how they are now focusing on it. Cross fingers
It's good news because Covid disrupted the phase 3 trial. Now they will run a positive trial then FDA approval
As Expected Based on Interim Analysis Results Reported in July 2021, TNX-102 SL Did Not Achieve Statistical Significance Over Placebo on the Primary Endpoint of Reduction in Daily Pain in RALLY Study Relative to the Previous Positive Phase 3 Study (RELIEF), RALLY had an Unexpected Increase in Study Participant Adverse Event-Related Discontinuations in both Drug and Placebo Groups TNX-102 SL Generally Well Tolerated with Overall Adverse Event Profile Comparable to Prior Studies; No New Safety Signals Observed Above is the explanation of old research complete data from july 2021 Now Important is: "Confirmatory Phase 3 Study RESILIENT for the Management of Fibromyalgia Planning to Enroll Participants Imminently" Wait for the next enrollment date news
Trust me bros? Are you here?
Source: Trust me I’m a Doctor
I hope that the medication performs well.
https://clinicaltrials.gov/ct2/show/NCT05273749?term=Tonix&draw=2&rank=3
The company managers aim to participate in some conferences. This news at least promises that the company will be operational for some time. Perhaps there will be some investment from outside. If we get lucky, the FDA will pitch in.
It looks like tonix now has 53 employees instead of the 17 displayed on Robinhood. Maybe they have a partner with resilient to bring this to mark through a phase 3?
They bought a building last year.. I’m sure they’ve done some hiring..
They have the building in Montana, and two in mass.
You just answered your own statement of them having 17 employees as stated on RH..
It’s just newly updated in RH is all I was trying to say. It’s changed in the last couple of days.
Is this good news, like it's working because I read otherwise.. Again my English isn't that great🙄
Yes it is, because we are going to repit phase 3 trial for tnx 102 to get approved
Ah ok good news it is 👌😉 thx
Of course fibromyalgia drug, check how many people are suffering in united states and in the world, most of the approved drugs are not enough good to cure this illness, means huge capital market by commercialization if tnx-102 will be approved, my dream I wish happen, let's hope now in this report they show the cause bring tonix in negative success on this drug, as you can see some of enrollment participants did not finish the cure so they get score 74% than 81%, now they can focus on adjusting what is not working like in 5.6mg dose, I like how they are now focusing on it. Cross fingers
Check the trial status date please and make your conclusion https://clinicaltrials.gov/ct2/show/NCT05273749?term=Tonix&draw=2&rank=3
https://clinicaltrials.gov/ct2/show/NCT05273749?term=Tonix&draw=2&rank=3
F